Loading...
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
de Boer, S Powell, M Mileshkin, L Katsaros, D Bessette, P Haie-Meder, C Ottevanger, P Ledermann, J Khaw, P Colombo, A
de Boer, S
Powell, M
Mileshkin, L
Katsaros, D
Bessette, P
Haie-Meder, C
Ottevanger, P
Ledermann, J
Khaw, P
Colombo, A
Citations
Altmetric:
Abstract
About 15% of patients with endometrial cancer have high-risk features and are at increased risk of distant metastases and endometrial cancer-related death. We designed the PORTEC-3 trial to investigate the benefit of adjuvant chemoradiotherapy compared with radiotherapy alone for women with high-risk endometrial cancer.
Description
Date
2016-07-07
Publisher
Collections
Files
Keywords
Type
Article
Citation
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. 2016: Lancet Oncol.